AnalystBook Research · Company Intelligence

Arteris, Inc.

AIPNasdaq

Built from Arteris, Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Arteris grew revenue 22.3% and turned free cash flow positive, but losses persisted and insiders sold heavily.

The read at a glance✓ Audited against SEC data
  • Business mixSemiconductor interconnect IPNote
  • RevenueRevenue grew 22.3% to $70.6MOK
  • CashFree cash flow was $5.3MOK
  • ProfitabilityNet loss was $34.7MWatch
  • Balance sheetEquity deficit widened to $14.6MWatch
  • Insiders0 buys / 115 sellsWatch
  • AccountingAltman-Z distress; EQ safeWatch

Business

Arteris provides semiconductor system IP, including Network-on-Chip interconnect technology and SoC automation software for chip designers.

Where the revenue comes from

Fiscal 2025, as Arteris, Inc. reports it. History and quarterly detail are in the app.

  • Licensing, support and maintenance$63.9M
  • Variable royalties and other$6.7M
  • Variable royalties$6.6M
  • Other$124K

Leadership changes

From Arteris, Inc.'s own filings, the day they're filed.

  • Joachim Kunkel · director · appointmenteff. 2024-09-16

Latest filings

  • 8-K · Company announcement2026-08-06
  • 10-Q · Quarterly report2026-08-06
  • 8-K · Company announcement2026-08-06
  • 8-K · Company announcement2026-06-04
  • 10-Q · Quarterly report2026-05-12
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • Main tension🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Arteris, Inc., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.